Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 5,766 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Refractory Malignancy Clear all

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: temsirolimus, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Lymphoma, Non-Hodgkin
Interventions: CC-99282, Obinutuzumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Boston, Massachusetts • Columbus, Ohio • Portland, Oregon + 1 more

Conditions: Cancer, Prostate
Interventions: Mitoxantrone, Siltuximab, Prednisone; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Norwalk, Connecticut • Port Saint Lucie, Florida • Atlanta, Georgia + 8 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Nemtabrutinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions: Marizomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lymphoma
Interventions: Vorinostat, Gemcitabine, Busulfan, Melphalan, Stem Cell Infusion, Rituximab, G-CSF, Palifermin, Dexamethasone acetate; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myeloproliferative Neoplasms
Interventions: AUY922; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions: Part 1 (Dose Escalation): Duvortuxizumab, Part 2 (Dose Expansion): Duvortuxizumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Detroit, Michigan • New York, New York • Columbus, Ohio + 3 more

Conditions: Ovarian Cancer
Interventions: becatecarin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Hodgkin's Lymphoma
Interventions: CAMPATH (alemtuzumab); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 10
States / cities: Colorado Springs, Colorado • Ocala, Florida • Park Ridge, Illinois + 7 more

Conditions: Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine Phosphate, GD2-CAR-expressing Autologous T-lymphocytes, Imaging Procedure, Magnetic Resonance Imaging of the Heart, Multigated Acquisition Scan, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 40 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2040
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 3 more

Conditions: Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions: alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Leukemia, Lymphocytic, Leukemia, Acute Lymphocytic Leukemia
Interventions: MAb 216, Vincristine; Drug
Lead sponsor: Steven E. Coutre; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lymphoma
Interventions: MGCD0103; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Leukemia
Interventions: 3 Day Thiarabine, 5 Day Thiarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Prostate Cancer
Interventions: Dasatinib, Docetaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Chicago, Illinois • Springfield, Illinois • Nyack, New York + 2 more

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
Interventions: Not listed
Lead sponsor: All4Cure; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Jacksonville, Florida • Des Moines, Iowa + 4 more

Conditions: Recurrent Small Cell Lung Carcinoma
Interventions: Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Topotecan Hydrochloride; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions: immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation; Biological · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Leukemia
Interventions: Moxetumomab Pasudotox; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
Interventions: EGFR806-specific chimeric antigen receptor (CAR) T cell; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 26 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: ABI-009, Gemcitabine; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Busulfan, Melphalan, Bortezomib, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation; Drug · Procedure
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 72 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 4
States / cities: New Brunswick, New Jersey • New York, New York • The Bronx, New York

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Search by objective public record fields.

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor

Marizomib Central Nervous System (CNS)

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies

Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML